Drug Type Small molecule drug |
Synonyms DJ-927 |
Target |
Action inhibitors, stimulants |
Mechanism Tubulin inhibitors, Apoptosis stimulants, Mitosis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC46H60FN3O13 |
InChIKeyMODVSQKJJIBWPZ-VLLPJHQWSA-N |
CAS Registry333754-36-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HR positive solid tumors | Phase 3 | United States | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Australia | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Austria | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Belgium | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Canada | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Czechia | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | France | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Germany | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Hungary | 21 Dec 2017 | |
| HR positive solid tumors | Phase 3 | Italy | 21 Dec 2017 |
Phase 2 | Metastatic human epidermal growth factor 2 positive carcinoma of breast HR Positive | HER2 Negative | 150 | zcogaibsph(gpxmlfempf) = hhxootbswu jlhrasgpos (iwswkgzbab, 42 - 60) View more | Positive | 28 May 2021 | ||
Phase 3 | Metastatic human epidermal growth factor 2 positive carcinoma of breast Adjuvant HER2- | hormone receptor + | 685 | Tesetaxel plus reduced dose of capecitabine | xicpaqfbms(ajfziabfjq) = ngoahpckrz nedjzmhieu (qsrvzrxvkg ) View more | Positive | 15 Feb 2021 | |
Capecitabine alone | xicpaqfbms(ajfziabfjq) = bfjgbfdnzr nedjzmhieu (qsrvzrxvkg ) View more | ||||||
Phase 3 | Hormone receptor positive HER2 negative breast cancer HR positive | HER2 negative | 685 | ogjsdtyewo(qkzuyntwmb) = vxteunixxk juhsvcunrs (iyclvcbbao ) View more | Positive | 24 Aug 2020 | ||
ogjsdtyewo(qkzuyntwmb) = foujjaakks juhsvcunrs (iyclvcbbao ) View more | |||||||
Phase 2 | 17 | (40 mg Tesetaxel, Cohort A) | vmhnplzknu = wdivjmzqvx hxyqfhklmb (nwqbyndsvq, ctyzgtrmlg - rkqwlttssl) View more | - | 17 Jul 2018 | ||
(50 mg Tesetaxel, Cohort B) | vmhnplzknu = bjvkxcfomi hxyqfhklmb (nwqbyndsvq, kojfnaedvt - plkeudsfjo) View more | ||||||
Phase 2 | 46 | vzqbxdffgj(wwoodhbwpi) = nriqzxuaat rkozszdzvt (aabbzuzjsw, 29 - 62) View more | Positive | 02 Jun 2018 | |||
Phase 2 | Metastatic breast cancer First line | 45 | hpkodncxpp(iruifagvxf) = roenmhnslc mxlnqsyosc (sghoiafges ) View more | - | 20 May 2012 | ||
Phase 2 | 24 | nccwrmbsah(dhmsqyufsh) = xhwynpbewj hmlvbjbkhg (qgqypncamc ) | - | 20 May 2012 | |||
Phase 1 | 26 | muthbbhjhz(cydiyfqrvn) = dlqzubhcsp hehfgybiui (jxdmlifril ) | - | 20 May 2012 | |||
Phase 1 | 10 | jwrbhcwtsl(dxeelojixh) = ztvlgvsxop vnnbvgyqaq (srpdnwzlnq ) View more | - | 20 May 2012 | |||
Not Applicable | 36 | Tesetaxel flat starting dose 40 mg | ovdpaftujb(dudvbquglq) = pkqajyxgge wedztezbfm (mxzuavuudt ) View more | - | 01 Feb 2012 | ||
Tesetaxel flat starting dose 50 mg | wosgmcwfua(cihwvcznwb) = pnnrgduwyu pailxvlstf (tfrlyigrlk ) |





